US EditionLobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Summary by Weatherford Democrat
4 Articles
4 Articles
All
Left
2
Center
Right
Weatherford Democrat+3 Reposted by 3 other sources
Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addictionOption for an additional $20 million investment in Cynaptec Pharmaceuticals…
Coverage Details
Total News Sources4
Leaning Left2Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
